Lack of clinical efficacy of imatinib in metastatic melanoma

Por Ugurel, S, Hildenbrand, R, Zimpfer, A, La Rosée, P, Paschka, P, Sucker, A, Keikavoussi, P, Becker, J C, Rittgen, W, Hochhaus, A, Schadendorf, D
Publicado em 2005

MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome

Por Hassel, J C, Sucker, A, Edler, L, Kurzen, H, Moll, I, Stresemann, C, Spieth, K, Mauch, C, Rass, K, Dummer, R, Schadendorf, D
Publicado em 2010

TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours

Por Griewank, K G, Murali, R, Schilling, B, Scholz, S, Sucker, A, Song, M, Süsskind, D, Grabellus, F, Zimmer, L, Hillen, U, Steuhl, K-P, Schadendorf, D, Westekemper, H, Zeschnigk, M
Publicado em 2013

NF1 mutations in conjunctival melanoma

Por Scholz, S. L., Cosgarea, I., Süßkind, D., Murali, R., Möller, I., Reis, H., Leonardelli, S., Schilling, B., Schimming, T., Hadaschik, E., Franklin, C., Paschen, A., Sucker, A., Steuhl, K. P., Schadendorf, D., Westekemper, H., Griewank, K. G.
Publicado no Br J Cancer (2018)

Differential influence of vemurafenib and dabrafenib on patients’ lymphocytes despite similar clinical efficacy in melanoma

Por Schilling, B., Sondermann, W., Zhao, F., Griewank, K. G., Livingstone, E., Sucker, A., Zelba, H., Weide, B., Trefzer, U., Wilhelm, T., Loquai, C., Berking, C., Hassel, J., Kähler, K. C., Utikal, J., Al Ghazal, P., Gutzmer, R., Goldinger, S. M., Zimmer, L., Paschen, A., Hillen, U., Schadendorf, D.
Publicado no Ann Oncol (2014)